88 related articles for article (PubMed ID: 16207152)
1. OASIS-HT: design of a pharmacogenomic dose-finding study.
Staessen JA; Kuznetsova T; Acceto R; Bacchieri A; Brand E; Burnier M; Celis H; Citterio L; de Leeuw PW; Filipovský J; Fournier A; Kawecka-Jaszcz K; Manunta P; Nikitin Y; O'Brien ET; Redón J; Thijs L; Ferrari P; Valentini G; Bianchi G
Pharmacogenomics; 2005 Oct; 6(7):755-75. PubMed ID: 16207152
[TBL] [Abstract][Full Text] [Related]
2. Main results of the ouabain and adducin for Specific Intervention on Sodium in Hypertension Trial (OASIS-HT): a randomized placebo-controlled phase-2 dose-finding study of rostafuroxin.
Staessen JA; Thijs L; Stolarz-Skrzypek K; Bacchieri A; Barton J; Espositi ED; de Leeuw PW; Dłużniewski M; Glorioso N; Januszewicz A; Manunta P; Milyagin V; Nikitin Y; Souček M; Lanzani C; Citterio L; Timio M; Tykarski A; Ferrari P; Valentini G; Kawecka-Jaszcz K; Bianchi G
Trials; 2011 Jan; 12():13. PubMed ID: 21235787
[TBL] [Abstract][Full Text] [Related]
3. Targeting Ouabain- and Adducin-dependent mechanisms of hypertension and cardiovascular remodeling as a novel pharmacological approach.
Ferrari P; Ferrandi M; Valentini G; Manunta P; Bianchi G
Med Hypotheses; 2007; 68(6):1307-14. PubMed ID: 17097240
[TBL] [Abstract][Full Text] [Related]
4. Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 2: clinical studies.
Lanzani C; Citterio L; Glorioso N; Manunta P; Tripodi G; Salvi E; Carpini SD; Ferrandi M; Messaggio E; Staessen JA; Cusi D; Macciardi F; Argiolas G; Valentini G; Ferrari P; Bianchi G
Sci Transl Med; 2010 Nov; 2(59):59ra87. PubMed ID: 21106941
[TBL] [Abstract][Full Text] [Related]
5. Rostafuroxin: an ouabain-inhibitor counteracting specific forms of hypertension.
Ferrari P
Biochim Biophys Acta; 2010 Dec; 1802(12):1254-8. PubMed ID: 20083196
[TBL] [Abstract][Full Text] [Related]
6. Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 1: experimental studies.
Ferrandi M; Molinari I; Torielli L; Padoani G; Salardi S; Rastaldi MP; Ferrari P; Bianchi G
Sci Transl Med; 2010 Nov; 2(59):59ra86. PubMed ID: 21106940
[TBL] [Abstract][Full Text] [Related]
7. Rostafuroxin: an ouabain antagonist that corrects renal and vascular Na+-K+- ATPase alterations in ouabain and adducin-dependent hypertension.
Ferrari P; Ferrandi M; Valentini G; Bianchi G
Am J Physiol Regul Integr Comp Physiol; 2006 Mar; 290(3):R529-35. PubMed ID: 16467500
[TBL] [Abstract][Full Text] [Related]
8. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
Kim SH; Kim YD; Lim DS; Yoon MH; Ahn YK; On YK; Lee JW; Kim IJ; Park JB; Kim JJ; Chung WS; Yang JY; Seo HS; Shin EK; Kim HS;
Clin Ther; 2007 Sep; 29(9):1924-36. PubMed ID: 18035192
[TBL] [Abstract][Full Text] [Related]
9. PST 2238: A new antihypertensive compound that modulates Na,K-ATPase in genetic hypertension.
Ferrari P; Ferrandi M; Tripodi G; Torielli L; Padoani G; Minotti E; Melloni P; Bianchi G
J Pharmacol Exp Ther; 1999 Mar; 288(3):1074-83. PubMed ID: 10027844
[TBL] [Abstract][Full Text] [Related]
10. Rostafuroxin protects from podocyte injury and proteinuria induced by adducin genetic variants and ouabain.
Ferrandi M; Molinari I; Rastaldi MP; Ferrari P; Bianchi G; Manunta P
J Pharmacol Exp Ther; 2014 Nov; 351(2):278-87. PubMed ID: 25187430
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the dose--response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension.
Puig JG; Schunkert H; Taylor AA; Boye S; Jin J; Keefe DL
Clin Ther; 2009 Dec; 31(12):2839-50. PubMed ID: 20110023
[TBL] [Abstract][Full Text] [Related]
12. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.
White WB; Lacourciere Y; Davidai G
Am J Hypertens; 2004 Apr; 17(4):347-53. PubMed ID: 15062889
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
14. Adducin and hypertension.
Staessen JA; Bianchi G
Pharmacogenomics; 2005 Oct; 6(7):665-9. PubMed ID: 16207143
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.
Lee H; Yang HM; Lee HY; Kim JJ; Choi DJ; Seung KB; Jeon ES; Ha JW; Rim SJ; Park JB; Shin JH; Oh BH
Clin Ther; 2012 Jun; 34(6):1273-89. PubMed ID: 22608107
[TBL] [Abstract][Full Text] [Related]
16. Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension--a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months rationale and study design.
Friedrich MG; Dahlöf B; Sechtem U; Unger T; Knecht M; Dietz R;
J Renin Angiotensin Aldosterone Syst; 2003 Dec; 4(4):234-43. PubMed ID: 14689371
[TBL] [Abstract][Full Text] [Related]
17. [Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals].
Weisser B; Gerwe M; Braun M; Funken C
Arzneimittelforschung; 2005; 55(9):505-13. PubMed ID: 16229114
[TBL] [Abstract][Full Text] [Related]
18. Antihypertensive treatment guided by genetics: PEARL-HT, the randomized proof-of-concept trial comparing rostafuroxin with losartan.
Citterio L; Bianchi G; Scioli GA; Glorioso N; Bigazzi R; Cusi D; Staessen JA; Cavuto S; Ferrandi M; Lanzani C; Li X; Lau LF; Chiang CE; Wang TD; Wang KL; Ferrari P; Manunta P
Pharmacogenomics J; 2021 Jun; 21(3):346-358. PubMed ID: 33649520
[TBL] [Abstract][Full Text] [Related]
19. A new antihypertensive agent that antagonizes the prohypertensive effect of endogenous ouabain and adducin.
Manunta P; Ferrandi M; Messaggio E; Ferrari P
Cardiovasc Hematol Agents Med Chem; 2006 Jan; 4(1):61-6. PubMed ID: 16529550
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and safety profile of amlodipine 5 mg/losartan 50 mg fixed-dose combination and amlodipine 10 mg monotherapy in hypertensive patients who respond poorly to amlodipine 5 mg monotherapy: an 8-week, multicenter, randomized, double-blind phase III noninferiority study.
Kang SM; Youn JC; Chae SC; Park CG; Yang JY; Kim MH; Hong TJ; Kim CH; Kim JJ; Shin DG; Jeong JW; Yoon JH; Park SH; Kwon J; Cho SY
Clin Ther; 2011 Dec; 33(12):1953-63. PubMed ID: 22136978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
